Trial Profile
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Daratumumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Colon cancer; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 142
- Sponsors Bristol-Myers Squibb
- 20 Jan 2024 64-month long term follow-up results from this trial presented at the 2024 Gastrointestinal Cancers Symposium.
- 13 Dec 2023 Planned End Date changed from 14 Dec 2024 to 16 Feb 2024.
- 13 Dec 2023 Planned primary completion date changed from 15 Dec 2023 to 16 Feb 2024.